Your browser doesn't support javascript.
loading
NHLRC2 variants identified in patients with fibrosis, neurodegeneration, and cerebral angiomatosis (FINCA): characterisation of a novel cerebropulmonary disease.
Uusimaa, Johanna; Kaarteenaho, Riitta; Paakkola, Teija; Tuominen, Hannu; Karjalainen, Minna K; Nadaf, Javad; Varilo, Teppo; Uusi-Mäkelä, Meri; Suo-Palosaari, Maria; Pietilä, Ilkka; Hiltunen, Anniina E; Ruddock, Lloyd; Alanen, Heli; Biterova, Ekaterina; Miinalainen, Ilkka; Salminen, Annamari; Soininen, Raija; Manninen, Aki; Sormunen, Raija; Kaakinen, Mika; Vuolteenaho, Reetta; Herva, Riitta; Vieira, Päivi; Dunder, Teija; Kokkonen, Hannaleena; Moilanen, Jukka S; Rantala, Heikki; Nogee, Lawrence M; Majewski, Jacek; Rämet, Mika; Hallman, Mikko; Hinttala, Reetta.
Afiliação
  • Uusimaa J; PEDEGO Research Unit and Medical Research Center Oulu, University of Oulu and Oulu University Hospital, PO Box 5000, 90014, Oulu, Finland. johanna.uusimaa@oulu.fi.
  • Kaarteenaho R; Department of Children and Adolescents, Oulu University Hospital, PO Box 23, 90029, Oulu, Finland. johanna.uusimaa@oulu.fi.
  • Paakkola T; Biocenter Oulu, University of Oulu, PO Box 5000, 90014, Oulu, Finland. johanna.uusimaa@oulu.fi.
  • Tuominen H; Research Unit of Internal Medicine, Respiratory Research, University of Oulu, PO Box 5000, 90014, Oulu, Finland.
  • Karjalainen MK; Medical Research Center Oulu and Unit of Internal Medicine and Respiratory Medicine, Oulu University Hospital, PO Box 20, 90029, Oulu, Finland.
  • Nadaf J; PEDEGO Research Unit and Medical Research Center Oulu, University of Oulu and Oulu University Hospital, PO Box 5000, 90014, Oulu, Finland.
  • Varilo T; Biocenter Oulu, University of Oulu, PO Box 5000, 90014, Oulu, Finland.
  • Uusi-Mäkelä M; Department of Pathology, Cancer and Translational Medicine Research Unit, University of Oulu, PO Box 5000, 90014, Oulu, Finland.
  • Suo-Palosaari M; Department of Pathology, Oulu University Hospital, PO Box 50, 90029, Oulu, Finland.
  • Pietilä I; PEDEGO Research Unit and Medical Research Center Oulu, University of Oulu and Oulu University Hospital, PO Box 5000, 90014, Oulu, Finland.
  • Hiltunen AE; McGill University and Génome Québec Innovation Centre, Montreal, QC, H3A 0G1, Canada.
  • Ruddock L; St. Jude Children's Research Hospital (SJCRH), 262 Danny Thomas Place, Memphis, TN, 38105, USA.
  • Alanen H; Department of Medical Genetics, University of Helsinki, Haartmaninkatu 8, 00251, Helsinki, Finland.
  • Biterova E; BioMediTech Institute and Faculty of Medicine and Life Sciences, University of Tampere, Tampere, Finland.
  • Miinalainen I; Department of Diagnostic Radiology and Medical Research Center Oulu, Oulu University Hospital and University of Oulu, PO Box 50, 90029, Oulu, Finland.
  • Salminen A; PEDEGO Research Unit and Medical Research Center Oulu, University of Oulu and Oulu University Hospital, PO Box 5000, 90014, Oulu, Finland.
  • Soininen R; Biocenter Oulu, University of Oulu, PO Box 5000, 90014, Oulu, Finland.
  • Manninen A; PEDEGO Research Unit and Medical Research Center Oulu, University of Oulu and Oulu University Hospital, PO Box 5000, 90014, Oulu, Finland.
  • Sormunen R; Biocenter Oulu, University of Oulu, PO Box 5000, 90014, Oulu, Finland.
  • Kaakinen M; Biocenter Oulu, University of Oulu, PO Box 5000, 90014, Oulu, Finland.
  • Vuolteenaho R; Faculty of Biochemistry and Molecular Medicine, University of Oulu, PO Box 5000, 90014, Oulu, Finland.
  • Herva R; Biocenter Oulu, University of Oulu, PO Box 5000, 90014, Oulu, Finland.
  • Vieira P; Faculty of Biochemistry and Molecular Medicine, University of Oulu, PO Box 5000, 90014, Oulu, Finland.
  • Dunder T; Biocenter Oulu, University of Oulu, PO Box 5000, 90014, Oulu, Finland.
  • Kokkonen H; Faculty of Biochemistry and Molecular Medicine, University of Oulu, PO Box 5000, 90014, Oulu, Finland.
  • Moilanen JS; Biocenter Oulu, University of Oulu, PO Box 5000, 90014, Oulu, Finland.
  • Rantala H; PEDEGO Research Unit and Medical Research Center Oulu, University of Oulu and Oulu University Hospital, PO Box 5000, 90014, Oulu, Finland.
  • Nogee LM; Biocenter Oulu, University of Oulu, PO Box 5000, 90014, Oulu, Finland.
  • Majewski J; Faculty of Biochemistry and Molecular Medicine, University of Oulu, PO Box 5000, 90014, Oulu, Finland.
  • Rämet M; Biocenter Oulu, University of Oulu, PO Box 5000, 90014, Oulu, Finland.
  • Hallman M; Faculty of Biochemistry and Molecular Medicine, University of Oulu, PO Box 5000, 90014, Oulu, Finland.
  • Hinttala R; Biocenter Oulu, University of Oulu, PO Box 5000, 90014, Oulu, Finland.
Acta Neuropathol ; 135(5): 727-742, 2018 05.
Article em En | MEDLINE | ID: mdl-29423877
ABSTRACT
A novel multi-organ disease that is fatal in early childhood was identified in three patients from two non-consanguineous families. These children were born asymptomatic but at the age of 2 months they manifested progressive multi-organ symptoms resembling no previously known disease. The main clinical features included progressive cerebropulmonary symptoms, malabsorption, progressive growth failure, recurrent infections, chronic haemolytic anaemia and transient liver dysfunction. In the affected children, neuropathology revealed increased angiomatosis-like leptomeningeal, cortical and superficial white matter vascularisation and congestion, vacuolar degeneration and myelin loss in white matter, as well as neuronal degeneration. Interstitial fibrosis and previously undescribed granuloma-like lesions were observed in the lungs. Hepatomegaly, steatosis and collagen accumulation were detected in the liver. A whole-exome sequencing of the two unrelated families with the affected children revealed the transmission of two heterozygous variants in the NHL repeat-containing protein 2 (NHLRC2); an amino acid substitution p.Asp148Tyr and a frameshift 2-bp deletion p.Arg201GlyfsTer6. NHLRC2 is highly conserved and expressed in multiple organs and its function is unknown. It contains a thioredoxin-like domain; however, an insulin turbidity assay on human recombinant NHLRC2 showed no thioredoxin activity. In patient-derived fibroblasts, NHLRC2 levels were low, and only p.Asp148Tyr was expressed. Therefore, the allele with the frameshift deletion is likely non-functional. Development of the Nhlrc2 null mouse strain stalled before the morula stage. Morpholino knockdown of nhlrc2 in zebrafish embryos affected the integrity of cells in the midbrain region. This is the first description of a fatal, early-onset disease; we have named it FINCA disease based on the combination of pathological features that include fibrosis, neurodegeneration, and cerebral angiomatosis.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Fibrose Pulmonar / Variação Genética / Encefalopatias / Doenças Neurodegenerativas / Peptídeos e Proteínas de Sinalização Intracelular / Angiomatose Tipo de estudo: Observational_studies / Prognostic_studies Limite: Animals / Humans / Infant / Male Idioma: En Revista: Acta Neuropathol Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Finlândia País de publicação: ALEMANHA / ALEMANIA / DE / DEUSTCHLAND / GERMANY

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Fibrose Pulmonar / Variação Genética / Encefalopatias / Doenças Neurodegenerativas / Peptídeos e Proteínas de Sinalização Intracelular / Angiomatose Tipo de estudo: Observational_studies / Prognostic_studies Limite: Animals / Humans / Infant / Male Idioma: En Revista: Acta Neuropathol Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Finlândia País de publicação: ALEMANHA / ALEMANIA / DE / DEUSTCHLAND / GERMANY